Chiasma (CHMA) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free CHMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineChiasma Craters on FDA Drug Rejectionthestreet.com - October 29 at 3:49 PMOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireglobenewswire.com - October 6 at 8:05 AMIronshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business Wirebusinesswire.com - September 28 at 8:11 AMCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.commarketscreener.com - September 16 at 8:20 AMAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comstreetinsider.com - September 16 at 8:20 AMAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKuk.finance.yahoo.com - September 7 at 9:30 PMMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comgurufocus.com - August 12 at 11:38 PMAmryt Reports Record Q2 2022 Results - GlobeNewswireglobenewswire.com - August 4 at 10:30 AMSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business Wirebusinesswire.com - July 12 at 3:44 PMSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo Financefinance.yahoo.com - July 12 at 8:07 AMGlobal Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo Financefinance.yahoo.com - June 20 at 4:17 PMAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.comgurufocus.com - June 18 at 10:01 AMAt 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo Financefinance.yahoo.com - June 16 at 12:09 PMThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswireglobenewswire.com - June 15 at 7:46 PMThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo Financefinance.yahoo.com - June 15 at 9:44 AMAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo Financefinance.yahoo.com - June 8 at 10:38 AMTop 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.comgurufocus.com - May 13 at 11:06 PMAmryt Reports Record Q1 2022 Results - Financial Postfinancialpost.com - May 6 at 7:50 PMAmryt Reports Record Q1 2022 Results - GlobeNewswireglobenewswire.com - May 4 at 2:58 PM2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - Stockhousestockhouse.com - May 4 at 9:55 AMInsights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - Benzingabenzinga.com - March 21 at 3:47 PMGlobal Oral Proteins and Peptides Market to 2032 - by - GlobeNewswireglobenewswire.com - March 16 at 7:46 AMAmryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.comstreetinsider.com - March 11 at 4:21 AMAmryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswireglobenewswire.com - March 9 at 10:49 AMWarm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswireprnewswire.com - February 28 at 12:22 PMGlobal Thermostable Vaccines and Thermostable Biologics Market to 2035 - by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region - ResearchAndMarkets.com - Business Wirebusinesswire.com - February 8 at 8:29 AMFood Allergy Market Anticipated to Witness Massive Growth with a Tremendous CAGR of 13.5% in the 7MM for the Study Period of 2018-30 | DelveInsight - PRNewswireprnewswire.com - January 31 at 3:50 PMForm 424B3 Amryt Pharma plc - StreetInsider.comstreetinsider.com - January 31 at 9:12 AMAmryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Financial Postfinancialpost.com - January 12 at 2:13 AMIN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York - Morningstarmorningstar.co.uk - January 11 at 4:12 PMVaccine mandates, inflation and remote workforces—here’s what mattered to CFOs this week - Fortunefortune.com - January 7 at 8:08 AMThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - Stockhousestockhouse.com - January 5 at 6:18 PM4D pharma appoints John Doyle as Chief Financial Officer - StreetInsider.comstreetinsider.com - January 5 at 8:17 AMAre you prepared for what the Supreme Court has to say on vaccine mandates? - Fortunefortune.com - January 4 at 9:57 AMThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - Yahoo Financefinance.yahoo.com - January 4 at 9:57 AMTBJ Plus: New CEO takes helm for Aerie Pharmaceuticals; $1.5B Novartis deal has Durham link; Thermo Fisher name rises in Wilmington - Triangle Business Journal - Triangle Business Journalbizjournals.com - December 24 at 6:54 PMVersantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO - Yahoo Financefinance.yahoo.com - December 22 at 1:29 PMNeuroSense: Advancing Generic Combos In Neurodegenerative Diseases - Seeking Alphaseekingalpha.com - December 22 at 1:16 AMVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - StreetInsider.comstreetinsider.com - December 4 at 8:39 PMVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - Business Wirebusinesswire.com - December 2 at 10:20 AMCatamaran Bio Announces Appointment of Tara Place as Vice President, Human Resources and Organizational Effectiveness - Yahoo Financefinance.yahoo.com - November 15 at 9:53 AMAmryt Pharma (AMYT) CEO Dr. Joe Wiley on Q3 2021 Results - Earnings Call Transcript - Seeking Alphaseekingalpha.com - November 7 at 8:45 AMAmryt Reports Strong Q3 2021 Results - GlobeNewswireglobenewswire.com - November 3 at 5:15 PMAmryt Reports Strong Q3 2021 Results - Form 6-K - Marketscreener.commarketscreener.com - November 3 at 12:14 PMAmryt Reports Strong Q3 2021 Results - Yahoo Financefinance.yahoo.com - November 3 at 7:14 AMNeuroSense Therapeutics announces the appointment of Mark Leuchtenberger as Chairman of the Board - Yahoo Financefinance.yahoo.com - September 29 at 8:17 PMIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition - Morningstarmorningstar.co.uk - September 14 at 1:43 PMIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition | Financial News - London South Eastlse.co.uk - September 14 at 6:56 AMAmryt Pharma Raises 2021 Revenue Guidance - MarketWatchmarketwatch.com - September 13 at 9:34 AMAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M - Yahoo Financefinance.yahoo.com - September 13 at 9:34 AM Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 CHMA Media Mentions By Week CHMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHMA News Sentiment▼0.460.33▲Average Medical News Sentiment CHMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHMA Articles This Week▼00▲CHMA Articles Average Week Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Generation Bio News G1 Therapeutics News Foghorn Therapeutics News Immutep News Merrimack Pharmaceuticals News Acrivon Therapeutics News Prelude Therapeutics News Galectin Therapeutics News Ovid Therapeutics News Design Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHMA) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
